DOI: 10.15406/jccr.205īackground: Idarucizumab is the only reversal agent specifically targeting dabigatran anticoagulation effect. Real world use of idarucizumab for dabigatran reversal in Aragón (Spain). Received: Novem| Published: December 19, 2020Ĭitation: Gavín O, Calvo JM, Dobón-Rebollo M, et al. José Manuel Calvo, 2 Manuela Dobón-Rebollo, 1 Irene Amarilla, 1 Nuria Fernández, 2 Luis Ignacio Sancho, 1 Isabel Cuesta, 3 Esther Franco-García, 5 Ángeles Pérez, 6 Laura Lacalle 7ġDepartment of Hematology and Hemotherapy, Lozano-Blesa University Hospital, SpainĢDepartment of Hematology and Hemotherapy, Miguel Servet Hospital, SpainģDepartment of Hematology and Hemotherapy, Hospital Obispo Polanco, SpainĤDepartment of Hematology and Hemotherapy, Hospital Comarcal de Barbastro, SpainĥDepartment of Hematology and Hemotherapy, Hospital Nuestra Señora de Gracia, SpainĦDepartment of Hematology and Hemotherapy, Hospital Royo Villanova, SpainħDepartment of Hematology and Hemotherapy, Hospital San Jorge, SpainĬorrespondence: Olga Gavín Sebastián, Haematology and Hemotherapy Service, Hospital Clínico Universitario Lozano Blesa, Avda.
Please type the correct Captcha word to see email ID.
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers.
0 kommentar(er)
